A prognostic molecular signature of hepatic steatosis is spatially heterogeneous and dynamic in human liver

By sjmartinez • December 11, 2024

Perry AS, Hadad N, Chatterjee E, Jimenez-Ramos M, Farber-Eger E, Roshani R, Stolze LK, Betti MJ, Zhao S, Huang S, Martens L, Kendall TJ, Thone T, Amancherla K, Bailin S, Gabriel CL, Koethe J, Carr JJ, Terry JG, Vaitinadin NS, Freedman JE, Tanriverdi K, Alsop E, Van Keuren-Jensen K, Sauld JFK, Mahajan G, Khan SS, Colangelo L, Nayor M, Fisher-Hoch S, McCormick JB, North KE, Below JE, Wells QS, Abel ED, Kalhan R, Scott C, Guilliams M, Gamazon ER, Fallowfield JA, Banovich NE, Das S, Shah R. A prognostic molecular signature of hepatic steatosis is spatially heterogeneous and dynamic in human liver. Cell Rep Med. 2024 Dec 4:101871. doi: 10.1016/j.xcrm.2024.101871. Epub ahead of print. PMID: 39657669.

Tags: diabetes, Endocrinology, liver-on-a-chip, Metabolic dysfunction-associated steatotic liver disease, non-alcoholic fatty liver disease, proteomics, Publications

FXYD2 marks and regulates maturity of (beta) cells via ion channel-mediated signal transduction

Tacto C, Tahbaz M, Salib A, Wang S, Cayabyab F, Choi J, Kim K, Hamba Y, Perez H, Gershon PD, Damoiseaux R, Oh TG, Yoshihara[...]

Determining Insulin Pump Candidacy: The Disconnect Between Clinical Care Guidelines and Clinical Practice

Everett E, Dao L, Munaganuru N, Udeze K, Gutierrez S, Gann S, Meda A, Tiu R, Arevalo A, Drexler C, Abdulrahman Y, Santana C, Moin[...]

mTOR inhibition triggers mitochondrial fragmentation in cardiomyocytes through proteosome-dependent prohibitin degradation and OPA-1 cleavage

Verdejo HE, Parra V, Del Campo A, Vasquez-Trincado C, Gatica D, Lopez-Crisosto C, Kuzmicic J, Venegas-Zamora L, Zuñiga-Cuevas U, Troncoso MF, Troncoso R, Rothermel BA,[...]